Therachon fetches $35 mln Series A

France-based Therachon, a developer of treatments for achondroplasia, has secured $35 million in Series A funding. OrbiMed led the round with participation from New Enterprise Associates, Inserm Transfer Initiative and Versant Ventures. In conjunction with the funding, Dr. Stephen Squinto, a venture partner at OrbiMed and Dr. Sara Nayeem, a principal at NEA, have been added to the board of directors.


Inari Medical ropes in $12.4 mln Series B

Irvine, Californa-based medical device company Inari Medical Inc has secured $12.4 million in Series B funding. The investors included Versant Ventures and US Venture Partners.


NeuWave Medical scores $25 mln Series C

Madison, Wisconsin-based medical device company NeuWave Medical Inc has closed $25 million in Series C financing. Versant Ventures led the round with participation from other investors that included H.I.G. BioVentures and Venture Investors. In conjunction with the funding, NeuWave has added Kirk Nielsen, managing director at Versant Ventures, to its board of directors.


VC-backed Glaukos Corp files for IPO

Laguna Hills, California-based Glaukos Corporation, a developer of treatments for glaucoma, has filed for an IPO. The number of shares that will be sold as well as the IPO’s pricing terms have yet to be set. The company plans on trading the stock on the NYSE under the ticker symbol “GKOS.” J.P. Morgan, BofA Merrill Lynch and Goldman, Sachs & Co are serving as the lead underwriters. Glaukos’ backers include OrbiMed Advisors, Frazier Healthcare Ventures, InterWest Partners, Domain Associates, Fjord Ventures, Montreaux Equity Partners and Versant Ventures

Laguna Pharmaceuticals grabs $30 mln Series B, also appoints CEO

Laguna Pharmaceuticals, formerly known as ChanRx, has closed $30 million in Series B financing. Versant Ventures and Frazier Healthcare led the round with participation from BioMed Ventures and previous backer Sante Ventures. In addition to the financing, Dr. Jerel Davis of Versant Ventures and Dr. Jamie Topper of Frazier Healthcare have been added to Laguna’s board of directors. Also, Laguna Pharmaceuticals has hired Bob Baltera as CEO. Previously, Baltera was CEO of Amira Pharmaceuticals. Laguna Pharmaceuticals is a biopharmaceutical company focused on treating atrial fibrillation and atrial flutter.


Deerfield leads $42.5 mln round for Audentes

San Francisco-based biotech firm Audentes Therapeutics has secured $42.5 million in Series B financing. Deerfield Management led the round with participation from Sofinnova Ventures, Venrock, OrbiMed, 5AM Ventures and Versant Ventures. As a result of the transaction, Jonathan Leff, a partner at Deerfield, will join Audentes’ board of directors.


Bayer to invest up to $25 mln in Versant Ventures’ newest fund

Versant Ventures‘ latest fund has added Bayer HealthCare as an LP. Bayer will invest up to $25 million in Versant Venture Capital V. The fund will back the development of new therapies “in areas of high unmet medical need.” In addition to investing in the fund, Bayer will join its advisory board.


Versant places Mazzo on administrative leave following indictment

Versant Ventures has placed operating partner Jim Mazzo on administrative leave following a federal grand jury indictment for alleged insider trading, a source at Versant confirmed. Both Mazzo and Versant have mutually agreed that Mazzo will suspend his work at the healthcare-focused venture firm until his legal matters are resolved.


Northleaf Capital holds second close on $233.5 mln for venture fund of funds

Northleaf Capital Partners has held a second closing on its Venture Catalyst Fund, bringing commitments to date to $233.5 million. The fund of funds, the first to be established under the Canadian government’s Venture Capital Action Plan, began investing in January and has made six investments, including three fund commitments to Versant Ventures, Georgian Partners and XPV Capital.

NVCF supports Versant Ventures’ Canadian expansion

Northleaf Venture Catalyst Fund has committed $10 million to healthcare-focused Versant Ventures. The capital will be used to support the firm’s continued Canadian expansion. Currently, Versant Ventures has incubators in Vancouver, Toronto and Montreal.


Venrock hires former Versant Ventures exec Samuels as partner

Venrock has hired Camille Samuels and Doug Dooley in the firm’s Palo Alto office. Samuels, a former managing director at Versant Ventures, joins as a partner to focus on biotech and consumer health, while expanding her focus into healthcare companies. Dooley, formerly an entrepreneur, will focus on infrastructure technologies and cloud-centric software.

Ceterix Orthopaedics nets $18 mln

Ceterix Orthopaedics has secured $18 million in financing. Previous backers Novo A/S, Versant Ventures and 5AM Ventures participated in the round. Armentum Partners provided financial advice to Ceterix on the transaction. Based in Menlo Park, Calif., Ceterix develops surgical tools for arthroscopic procedures.

PE HUB Community

Join the 12525 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget